...
首页> 外文期刊>Thoracic cancer. >Role of radiotherapy in treating patients with primary malignant mediastinal non‐seminomatous germ cell tumor: A 21‐year experience at a single institution
【24h】

Role of radiotherapy in treating patients with primary malignant mediastinal non‐seminomatous germ cell tumor: A 21‐year experience at a single institution

机译:放射疗法在治疗原发性恶性纵隔非精原细胞性生殖细胞肿瘤患者中的作用:在单个机构中拥有21年的经验

获取原文
           

摘要

AbstractBackgroundThe aim of this study was to investigate the clinical characteristics and outcomes of patients with primary malignant mediastinal non-seminomatous germ cell tumor (MMNSGCT) by comparing the efficacies of different treatment modalities.MethodsThe charts of 62 consecutive patients with MMNSGCT between 1990 and 2010 were reviewed. Analyses included Kaplan-Meier survival and Cox multivariate regression.ResultsThere was sufficient data of 61 patients for inclusion in the study. The median age was 25 years. At diagnosis, 35 patients had tumors located in the mediastinum, 26 had lung and/or distant metastases. At a median follow-up of 47.2 months, 32 patients had died and 43 had developed progressive disease. The one, three, and five-year overall survival (OS) and progression-free survival (PFS) rates were 72.1%, 50.8%, 49.2% and 47.5%, 32.8%, 32.8%, respectively. Patients who received radiotherapy in the primary treatment regimen showed improved five-year OS (68.2% vs. 38.5%, P = 0.043), PFS (45.5% vs. 20.5%, P = 0.023), and local recurrence-free survival (LRFS) (77.3% vs. 38.5%, P = 0.003) compared with those who did not receive radiotherapy. Multivariate analysis revealed that radiotherapy was an independent prognostic factor of five-year OS (hazard ratio [HR] 0.39, P = 0.037), PFS (HR 0.42, P = 0.017), and LRFS (HR 0.31, P = 0.019).ConclusionRadiotherapy in a chemotherapy-based treatment regimen could significantly reduce local recurrence and improve survival of MMNGCT patients.
机译:摘要背景:本研究旨在通过比较不同治疗方式的疗效来调查原发性恶性纵隔非精原细胞性生殖细胞瘤(MMNSGCT)患者的临床特征和结果。方法1990年至2010年连续62例MMNSGCT患者的图表如下:已审查。结果包括61名患者的足够数据可纳入研究。中位年龄为25岁。在诊断时,有35例肿瘤位于纵隔,26例有肺和/或远处转移。中位随访时间为47.2个月,死亡32例患者,其中43例发展为疾病。一年,三年和五年的总生存率(OS)和无进展生存率(PFS)分别为72.1%,50.8%,49.2%和47.5%,32.8%,32.8%。在主要治疗方案中接受放射治疗的患者表现出改善的五年OS(68.2%vs. 38.5%,P = 0.043),PFS(45.5%vs. 20.5%,P = 0.023)和局部无复发生存率(LRFS) )(77.3%vs. 38.5%,P = 0.003)与未接受放射治疗的患者相比。多因素分析显示,放疗是五年OS的独立预后因素(危险比[HR] 0.39,P =(0.037),PFS(HR 0.42,P = 0.017)和LRFS(HR 0.31,P = pro0.019)。以化学疗法为基础的治疗方案可以显着减少MMNGCT患者的局部复发并提高生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号